Optive® (Optiv®)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Similar drugsTo uncover
Dosage form: & nbspeye drops
Composition:

1 ml of the preparation contains:

active substances: carmellose sodium (type 7H3SXF 10-15) 1.75 mg, carmellose sodium (type 7M8SFPH) 3.25 mg, glycerol 9.00 mg;

Excipients: Erythritol 2,50 mg, Levocarnitine 2.50 mg, Boric acid 7.00 mg, sodium borate decahydrate 2.00 mg, sodium citrate dihydrate 1.00 mg, potassium chloride 1.40 mg, calcium chloride dihydrate 0.06 mg, magnesium chloride hexahydrate 0.06 mg, oxychloro complex stabilized [sodium chlorite, sodium chlorate, chlorine dioxide] 0.10 mg, water purified to 1.00 ml.

Description:

A clear, colorless solution.

Pharmacotherapeutic group:Keratoprotective agent
ATX: & nbsp
  • Artificial tears and other indifferent drugs
    • Pharmacodynamics:

    Carmellose sodium and glycerol have the properties of the corneal epithelium protector, improve the hydration of the cornea with reduced secretion of tear fluid and increase the stability of the tear film.

    Pharmacokinetics:

    Studies of pharmacokinetics in humans have not been conducted.

    Indications:

    Symptomatic treatment of the "dry eye" syndrome.

    Contraindications:

    Hypersensitivity to the components of the drug, children under 18 years of age (no experience of use).

    Carefully:

    During pregnancy and during breastfeeding (due to limited data).

    Pregnancy and lactation:

    Strictly controlled studies in pregnant women and nursing mothers were not conducted. In animal studies, adverse effects of the active components of the drug were not detected.

    Opto® is not absorbed from the mucosal surface, so there are no objective prerequisites for the possible excretion of its components with breast milk.

    Use of the drug during pregnancy and during lactation is possible with caution.

    Dosing and Administration:

    The drug is instilled in 1-2 drops in the conjunctival sac as needed.

    Side effects:

    When using the drug, the development of the following adverse reactions with the indicated frequency is possible: very often (≥10%), often (≥1%, <10%), infrequently (≥0,1%, <1%), rarely (≥0, 01%, <0.1%), very rarely (0.01%).

    Disorders from the side of the organ of vision:

    often - congestion hyperemia, eyelid hyperemia, blurred vision, dry eye, discomfort when instilled, itching and irritation of the eyes, crust formation at the edge of the eyelid.

    In the postmarketing period, there were reports of the following undesirable reactions of the drug Optiv® (frequency unknown): pain in the eye area,the appearance of the eye, the sensation of a foreign body in the eye, the swelling of the eyelid, increased tearing, photophobia.

    Overdose:

    Information on cases of overdose of the drug Optiv® is absent.

    Interaction:

    Data on the drug interaction of the drug Optiv® is not available.

    When appointing with other local ophthalmologic agents, the interval between instillation of the Optiv® preparation and other eye drops should be at least 5 minutes in order to exclude the possibility of "washing out" the drug.

    Special instructions:

    The drug is intended for topical use only.

    Do not use if the integrity of the film, covering the neck of the bottle, clouding the solution or changing its color.

    Do not touch the tip of the pipette to any surface, including the conjunctiva, to avoid contamination of the contents of the vial.

    It is necessary to close the bottle immediately after using the drug.

    The shelf life of the drug after the first opening of the vial is 28 days.

    Consult your doctor if you have pain in the eye area, impaired vision, prolonged hyperemia or irritation of the eye mucosa.

    Also seek advice if there is no improvement from the use of the drug and / or if you have other undesirable effects that build up or are not resolved within 72 hours.

    Effect on the ability to drive transp. cf. and fur:

    If, after instillation, blurring of vision is noted, it is necessary to refrain from driving vehicles and practicing potentially dangerous activities that require an increased concentration of attention and speed of psychomotor reactions, before it is restored.

    Form release / dosage:

    Eye drops.

    Packaging:

    By 10.0 or 15.0 ml of the drug into a dropper bottle of low-density polyethylene with a capacity of 10 or 15 ml, respectively, with a screw cap made of impact-resistant polystyrene, which is sealed with a shrinkable polymer film.

    One bottle-dropper along with the instruction for use is placed in a cardboard box.

    Storage conditions:

    At a temperature of no higher than 25 ° C.

    Keep out of the reach of children.

    Shelf life:

    2 years.

    Do not use after the expiration date stated on the package.

    Terms of leave from pharmacies:Without recipe
    Registration number:LP-001549
    Date of registration:29.02.2012 / 31.05.2017
    Expiration Date:Unlimited
    Date of cancellation:2017-02-28
    The owner of the registration certificate:Allergen, Inc.Allergen, Inc. USA
    Manufacturer: & nbsp
    Representation: & nbspAllergen of CIS SARL. LtdAllergen of CIS SARL. LtdRussia
    Information update date: & nbsp09.06.2017
    Illustrated instructions
      Instructions
      Up